ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorLaforest, Anais-
Autor(es): dc.creatorAparicio, Thomas-
Autor(es): dc.creatorZaanan, Aziz-
Autor(es): dc.creatorPittella-Silva, Fabio-
Autor(es): dc.creatorDidelot, Audrey-
Autor(es): dc.creatorDesbeaux, Aurélien-
Autor(es): dc.creatorLe Corre, Delphine-
Autor(es): dc.creatorBenhaim, Leonor-
Autor(es): dc.creatorPallier, Karine-
Autor(es): dc.creatorAust, Daniela-
Autor(es): dc.creatorPistorius, Steffen-
Autor(es): dc.creatorBlons, Hélène-
Autor(es): dc.creatorSvrcek, Magali-
Autor(es): dc.creatorLaurent-Puig, Pierre-
Data de aceite: dc.date.accessioned2024-10-23T15:19:19Z-
Data de disponibilização: dc.date.available2024-10-23T15:19:19Z-
Data de envio: dc.date.issued2022-10-06-
Data de envio: dc.date.issued2022-10-06-
Data de envio: dc.date.issued2014-07-
Fonte completa do material: dc.identifierhttps://repositorio.unb.br/handle/10482/45004-
Fonte completa do material: dc.identifierhttps://doi.org/10.1016/j.ejca.2014.04.007-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/880114-
Descrição: dc.descriptionAim of the study Small bowel adenocarcinoma (SBA) is a rare and aggressive tumour with poor outcomes. Because of its low incidence, the number prospective studies remains insufficient leading to poor knowledge and absence of standard of care. Aiming to better understand small bowel carcinogenesis we investigated the frequency of somatic mutations in a large data set of patients in more than 740 mutational hotspots among 46 genes. Methods In total, 83 SBA cases were selected from two European databases. The sequencing was performed using the Ion 316 Chip. Additionally we looked into ERBB2 expression and microsatellite instability (MSI) status. Results The tumours most frequently were duodenal (47%) and stage ⩾3 (63%). Eight genes were mutated with a frequency >5%: KRAS, TP53, APC, SMAD4, PIK3CA, ERBB2, BRAF and FBXW7. ERBB2 alterations are present in 10 patients (12%) through mutations (7 cases) or amplifications (3 cases). ERBB2 mutations were significantly associated with duodenal tumour location (P = 0.04). In this group, there was a positive association with dMMR status (P = 0.006) and APC mutation (P = 0.02) but negative association with p53 mutations (P = 0.038). Conclusions This study describes the first large screening of somatic mutations in SBA using next generation sequencing. The ERBB2 mutation was revealed to be one of the most frequent alterations in SBA with a distribution dependent on tumour location. In most cases ERBB2 mutation was identical (p.L755S). In clinical practice, this may suggest that more than 10% of the patients with SBA could be treated using an anti-ERBB2-targeted agent.-
Publicador: dc.publisherElsevier-
Relação: dc.relationhttps://www.sciencedirect.com/science/article/pii/S0959804914005929?via%3Dihub#!-
Direitos: dc.rightsAcesso Restrito-
Palavras-chave: dc.subjectGenes-
Palavras-chave: dc.subjectMutações-
Palavras-chave: dc.subjectIntestino delgado - câncer-
Palavras-chave: dc.subjectSequenciamento genômico-
Título: dc.titleERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional – UNB

Não existem arquivos associados a este item.